A nurse is teaching a client who has rheumatoid arthritis about a new prescription for infliximab. Which of the following statements should the nurse include in the teaching?

Infliximab is a tumor necrosis factor (TNF)-alpha inhibitor, a type of biologic response modifier used to treat autoimmune conditions including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. Because TNF-alpha plays an important role in immune defense, blocking it significantly increases the client's susceptibility to serious infections, including bacterial, fungal, opportunistic infections, and reactivation of latent tuberculosis. Clients must be screened for latent TB before starting infliximab and should be taught to report any signs of infection immediately. Increased photosensitivity is not a recognized adverse effect of infliximab; this is more characteristic of certain antibiotics or methotrexate. Infliximab is administered as an intravenous infusion at weeks 0, 2, and 6 for induction, and then every 8 weeks for maintenance — not weekly for 6 weeks, making that statement incorrect. A metallic taste is associated with other medications such as metronidazole or some chemotherapy agents, not infliximab infusions. Nurses providing client education about biologic agents must emphasize infection risk, the importance of reporting fever or illness, and the need to avoid live vaccines while on therapy.